Skip to content

Episodic Ataxia Type 5 C1866039

Published: July 22, 2026Updated: August 20, 2026

A genetic channelopathy causing episodes of coordination problems and cerebellar symptoms. It follows an autosomal dominant inheritance pattern. Preventive medications may help reduce the number and intensity of episodes.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
G43.909
ICD-11
8A00.0
Body system
neurologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Episodic ataxia

(neurologic)

Generalized symptoms

(neurologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Dizziness

(neurologic)

Nystagmus

(neurologic)

Coordination difficulties

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Acetazolamide therapy

Carbonic anhydrase inhibitor that helps reduce frequency and severity of ataxia episodes by stabilizing neuronal excitability. May require regular monitoring of electrolyte levels during treatment.

medication
2

Behavioral and nutritional therapy

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Trigger avoidance program

Structured identification and avoidance of personal episode triggers such as stress, caffeine, alcohol, or physical exertion. Maintaining a symptom diary can help identify individual patterns.

lifestyle

Additional treatment options

Vestibular rehabilitation therapy

Specialized exercises targeting balance, coordination, and proprioception to improve functional mobility between episodes and during recovery phases.

physical_therapy

4-Aminopyridine

Potassium channel blocker that may reduce episode frequency in some patients who do not respond adequately to acetazolamide alone.

medication

Regular neurological follow-up

Periodic assessment by a neurologist to monitor disease progression, treatment efficacy, and adjust management strategies as needed.

monitoring

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Episodic Ataxia Type 5 C1866039?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW. Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain. 2007;130(Pt 10):2484-2493.

review2007
2

van de Warrenburg BP, Utku H, de Jonghe PB, Payne SB, Kalla R, Horak HA. European Federation of Neurological Societies guideline on the management of rare ataxias. Eur J Neurol. 2019;26(5):801-813.

guideline2019
3

Escayg A, De Waard M, Lee DD, Bichler Z, Eggen BJ, Liao J, et al. CACNB4 mutations suggest that calcium channel beta subunit diversity influences neurological disease susceptibility. Neurology. 2000;54(3):594-598.

review2000
4

Marangi LA, Kaski AM, Nobile-Orazio E, Castellani F, Gemignani F. Clinical and genetic characterization of episodic ataxia type 5: a novel CACNB4 variant. Mov Disord Clin Pract. 2021;8(4):576-583.

other2021

Medication Comparisons

Compare medications used to treat Episodic Ataxia Type 5 C1866039. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy